Avalyn Pharma Inc.
AVLN Nasdaq
SEC CIK 1540171
Follow Avalyn Pharma
Weekly email: filings, results, news
Net income
−$28.9M
−43.3% vs same quarter last year
EPS, diluted
−$0.98
+94.4% vs same quarter last year
Operating cash flow
−$26.1M
−26% vs same quarter last year
Operating income
−$31.3M
−43.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
News
No stories filed under Avalyn Pharma yet - coverage appears here as the news feed clusters it.